Synthorx (NASDAQ:THOR) Lowered to “Hold” at Zacks Investment Research

Zacks Investment Research cut shares of Synthorx (NASDAQ:THOR) from a buy rating to a hold rating in a research note released on Thursday, Zacks.com reports.

According to Zacks, “Synthorx Inc. is a biopharmaceutical company which focuses on cancer and autoimmune disorders. The company’s product pipeline consists of THOR-707, IL-2 autoimmune synthorin, IL-10 synthorin and IL-15 synthorin which are in clinical stage. Synthorx Inc. is based in La Jolla, CA. “

Separately, HC Wainwright reaffirmed a buy rating and issued a $30.00 target price on shares of Synthorx in a research note on Wednesday, May 1st. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock currently has an average rating of Buy and a consensus target price of $22.67.



Shares of NASDAQ THOR traded down $0.68 during trading on Thursday, reaching $14.99. The company had a trading volume of 20,824 shares, compared to its average volume of 101,386. Synthorx has a 52 week low of $11.00 and a 52 week high of $23.53. The stock has a market cap of $470.12 million and a PE ratio of -2.27. The business’s 50 day moving average is $14.93.

Synthorx (NASDAQ:THOR) last announced its earnings results on Thursday, August 1st. The medical instruments supplier reported ($0.39) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.36) by ($0.03). As a group, equities analysts anticipate that Synthorx will post -1.81 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently bought and sold shares of THOR. Strs Ohio bought a new stake in shares of Synthorx during the first quarter worth approximately $38,000. Wells Fargo & Company MN raised its stake in shares of Synthorx by 156.5% during the second quarter. Wells Fargo & Company MN now owns 12,056 shares of the medical instruments supplier’s stock worth $162,000 after buying an additional 7,356 shares during the last quarter. Matisse Capital raised its stake in shares of Synthorx by 16.9% during the first quarter. Matisse Capital now owns 64,333 shares of the medical instruments supplier’s stock worth $1,310,000 after buying an additional 9,300 shares during the last quarter. Emory University bought a new stake in shares of Synthorx during the first quarter worth approximately $2,439,000. Finally, FMR LLC bought a new stake in shares of Synthorx during the fourth quarter worth approximately $38,559,000. 66.08% of the stock is owned by institutional investors and hedge funds.

About Synthorx

Synthorx, Inc, a biopharmaceutical company, focuses on the development of cytokine Synthorin programs for the treatment of cancer and autoimmune disorders in the United States. The company's lead product candidate is THOR-707, a variant of recombinant human IL-2 that is in the development in various solid tumor types as a single agent and in combination with an immune checkpoint inhibitor.

Featured Story: What are Bollinger Bands?

Get a free copy of the Zacks research report on Synthorx (THOR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Synthorx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthorx and related companies with MarketBeat.com's FREE daily email newsletter.